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Abstract: Bipolar disorder (BD) is a debilitating and difficult-to-treat psychiatric disease that 
presents a serious burden to patients’ lives as well as health care systems around the world. The 
essential diagnostic criterion for BD is episodes of mania or hypomania; however, the patients 
report that the majority of their time is spent in a depressive phase. Current treatment options 
for this component of BD have yet to achieve satisfactory remission rates. Lurasidone is a drug 
in the benzisothiazole class approved by the US Food and Drug Administration in June 2013 
for the acute treatment of bipolar depression. Its pharmacological profile features high-affinity 
antagonism at D
2
, 5-HT
2A
, and 5-HT
7
 receptors; moderate-affinity antagonism at α
2C
-adrenergic 
receptors; low- to very low-affinity antagonism at α
1A
-adrenergic, α
2A
-adrenergic, H
1
, M
1
, and 
5-HT
2C
 receptors; and high-affinity partial agonism at 5-HT
1A
. Preliminary findings from two 
recent double-blinded clinical trials suggest that lurasidone is efficacious in treating bipolar I 
depression, with clinical effects manifesting as early as the first 2–3 weeks of treatment (as 
measured by the Montgomery–Åsberg Depression Rating Scale and Clinical Global Impressions 
Scale for use in bipolar illness). Its therapeutic benefit appears to be comparable to the current 
US Food and Drug Administration-indicated treatments: quetiapine and olanzapine–fluoxetine, 
according to a measure of effect size known as number needed to treat. These studies reported 
relatively limited extrapyramidal and metabolic side effects as a result of treatment with lurasi-
done, with the most common side effect being nausea. Safety data drawn from these studies, as 
well as a more extensive body of schizophrenia research, indicate that in comparison with other 
atypical antipsychotics, treatment with lurasidone is less likely to result in metabolic side effects 
such as weight gain or disturbances of serum glucose or lipid levels. Lurasidone holds clinical 
potential as a novel, efficacious pharmacological treatment for bipolar depression. However, 
current data on its use for the treatment of BD are limited, and more extensive research, both 
longer in duration as well as independently conducted, is needed.
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Introduction
Bipolar disorder (BD) is a chronic and often severely disabling psychiatric condition. Col-
lectively, forms of BD (type I, type II, or not otherwise specified) are estimated to affect 
approximately 4.4% of Americans or about 12.7 million people.1,2 Worldwide, BD was 
ranked 18th by the World Health Organization in worldwide causes of years lived with 
disability, surpassing all forms of cancer.3 The economic burden in terms of cost of health 
care for patients with BD is estimated to be four times greater than that for patients without 
mental disorders.4 Overall, the total economic burden of BD to the US economy is difficult 
to estimate, but one 24-year-old study approximated the figure to be nearly $45 billion,5 
adjusted for inflation; in 2015, the estimate will be closer to $78 billion.6
The essential diagnostic criterion for BD is episodes of elevated/irritable mood, 
usually either mania (type I) or hypomania (type II).7 Despite this, BD patients have 
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reported through surveys and clinical status ratings that they 
spend the majority of their time in a depressive phase8 and 
that these episodes are more disruptive to their functioning 
than mania.9 Bipolar depression is notably distinct from 
unipolar depression in that its phenomenological features 
more commonly include psychosis, depressive mixed state, 
anxiety, agitation, anergic depression, irritability, and anger 
attacks.10 Moreover, the increased risk of suicide in patients 
with BD (whose rates of suicide are one of the highest among 
patients with psychiatric illness)11,12 is observed predomi-
nantly during the depressive phase.11,12
Treatment of BD aims for remission of symptoms, both 
manic and depressive. Efficacious treatment, however, is 
not easy to achieve; the remission rate for bipolar mania and 
depression after acute treatment is reported to be approxi-
mately 40%–50% and 25%–60%, respectively.13,14 (This esti-
mate is possibly misrepresentative of long-term remission, as 
a common feature of BD depression is insensitivity to acute 
treatment).10 Factors complicating treatment include toler-
ance to medications and significant likelihood of relapse,15 
even with continual pharmacological maintenance.
Pharmacotherapy options for BD are typically grouped by 
the targeted symptoms. Lithium, first- and second-generation 
antipsychotics, valproate, and carbamazepine are usually 
prescribed for the treatment of acute mania, while quetia-
pine, olanzapine–fluoxetine, lamotrigine (maintenance), 
and antidepressants in conjunction with an antimanic agent 
(acute) are usually prescribed for the treatment of depres-
sive symptoms.16,17 Currently, only quetiapine, olanzapine–
fluoxetine combination, and lurasidone are approved by 
the Food and Drug Administration (FDA) to treat bipolar 
depression. Further treatment options are greatly needed, as 
bipolar depression, the most prevalent and fatal feature of 
BD, is often not well covered by these regimens and nonre-
sponse to first-line options is perhaps as high as 40%.18 In 
a review of therapeutic options for treatment-resistant BD 
depression, Sienaert et al found that although promising, 
current research for this diagnosis is scarce.18 In this review, 
we aim to summarize recent available literature regarding 
the compound lurasidone and its role in the treatment of 
bipolar depression.
Pharmacology and pharmacokinetics
The biological basis of BD depression remains unknown: one 
current theory, developed by Fountoulakis et al19 postulates 
that unlike unipolar depression, norepinephrine reuptake 
and 5-HT
1A
 agonism are heavily implicated as core deficits. 
Pharmacologically, lurasidone is appropriate to treat these 
features, though long-term clinical data in conjunction with 
neurobiological models remain to be established.
Lurasidone or (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-
benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylm-
ethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione 
hydrochloride20 (as it is known chemically) (Figure 1 for 3D 
chemical structure) is a chemical in the benzisothiazole class, 
structurally related to perospirone and ziprasidone, as well 
as the benzisoxazole derivative risperidone.21 In vitro assays 
have demonstrated that lurasidone is a full antagonist at D
2
 
(K
i
=1.68 nM)22 (Table 1) and 5-HT
2A
 (K
i
=2.03 nM) receptor 
subtypes, a property shared by other atypical antipsychotics 
such as risperidone, olanzapine, quetiapine, clozapine, and 
aripiprazole.22 In comparison to similar drugs, lurasidone 
has the highest binding affinity for the 5-HT
7
 receptor 
(K
i
=0.5 nM).22 Other notable pharmacological properties 
include moderate-affinity α
2C
-adrenergic antagonism, par-
tial agonism at the 5-HT
1A
 receptor, and low affinity for the 
muscarinic (M
1
), histamine (H
1
) (both K
i
 values .1,000 nM), 
5-HT
2C
 (415 nM), α
1A
 (47.9 nM), and α
2A
 (40.7 nM) adren-
ergic receptors.23 Table 1 shows the pharmacological profile 
of lurasidone.
There is limited evidence that lurasidone may provide 
cognitive benefits due to several properties of its binding 
profile. Blocking activity at the 5-HT
7
 receptor (K
i
=0.5 nM) 
may contribute to therapeutic benefits as suggested by a study 
of the drug’s effect on learning when given in conjunction 
with an N-methyl-d-aspartate blocker.22 Ishiyama et al found 
that rats were prevented from learning a passive-avoidance 
shock response when administered with N-methyl-d-aspar-
tate receptor antagonist dizocilpine; this inhibition, however, 
was dose dependently reversed when the animals were given 
lurasidone, regardless of pre- or post-training administration. 
Figure 1 Three-dimensional structure of lurasidone, also known as (3aR,4S, 
7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexy-
lmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride or 
Latuda.
Notes: Molecular weight is 529.13698 g/mol and molecular formula is 
C28H37ClN4O2S. Teal atoms represent hydrogen, gray atoms carbon, red atoms 
oxygen, blue atoms nitrogen, and the yellow atom a sulfur; the associated hydrogen 
chloride salt is not pictured.18
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This effect suggests that lurasidone may contribute to restora-
tion of the memory consolidation process and may therefore 
have benefits in reducing the cognitive impairments observed 
in bipolar depression.23
Additionally, the drug acts with moderate binding affin-
ity as an antagonist at α
2C
-adrenergic receptor (K
i
=10.8 nM), 
overexpression of which has been shown to increase impair-
ment in the Morris water maze,24 further lending support to 
possible procognitive effects of lurasidone.
Lurasidone also interacts as a partial agonist at the 5-HT
1A
 
receptor (K
i
=6.75 nM),22 activation of which has been shown 
to increase adult neuronal proliferation in the dentate gyrus 
of the hippocampus.25 This influence in neurogenesis may 
be of cognitive therapeutic benefit, as demonstrated by pilot 
clinical studies using antipsychotics with adjunct 5-HT
1A
 
agonists.26
Overall, based on neurobiological evidence, lurasi-
done may provide advantages in learning and memory via 
high-affinity 5-HT
7
 and moderate-affinity α
2C
-adrenergic 
antagonism, as well as partial agonism at the 5-HT
1A
 
receptor.22,23,27
The 5-HT
7
 receptor-blocking activity of lurasidone may 
also underlie antidepressant properties of the drug. Selective 
antagonists and experiments in 5-HT
7
 gene knockout animals 
have demonstrated anxiolytic-like and antidepressant-like 
effects in rodents, which demonstrated improvement on the 
Vogel drinking, elevated plus-maze, four-plate test, forced 
swimming, and tail suspension tests.28,29 It is far from proven 
that these tests translate well to human depression, unipolar or 
bipolar, but they may be useful screens. These mood effects 
may be mediated by a cortical and hippocampal dopamine 
efflux caused by activity at the 5-HT
7
 and 5-HT
1A
 receptors.30
Similarly, lurasidone injected subcutaneously in ado-
lescent rats modulates levels of brain-derived neurotrophic 
factor by preventing adult decreases in brain-derived 
neurotrophic factor expression normally seen in animals 
exposed to prenatal stress.31 This effect provides support 
for the neurotrophic hypothesis of depression32 and further 
implicates lurasidone as a potentially beneficial therapy for 
bipolar depression.
Clinically, one of the most promising features of lur-
asidone is its low affinity for muscarinic (M
1
), histamine 
(H
1
) (both K
i
 values .1,000 nM), 5-HT
2C
 (415 nM), α
1A
- 
(47.9 nM), and α
2A
-(40.7 nM) adrenergic receptors.33 Well-
known side effects of many antipsychotics, such as sedation, 
weight gain, and negative cognitive symptoms, have been 
only minimally observed in both animal and human trials 
of lurasidone (see “Safety and tolerability” section). This is 
thought to be due to the low levels of activity of lurasidone 
at H
1
34 and 5-HT
2C
35 receptors.22 Decreased interaction with 
muscarinic and α-1 adrenergic receptors may prevent nega-
tive cognitive and cardiovascular side effects.36
Despite being a high-affinity D
2
 receptor antagonist, 
historically a harbinger of severe neurological side effects,33 
in vivo studies of lurasidone to date have observed fewer 
central nervous system’s depressive effects, extrapyramidal 
symptoms, and anticholinergic side effects (such as dry 
mouth or amnesia)22 than other typical and even other atypical 
antipsychotics. This may be explained in part by the drug’s 
receptor saturation point. A study of lurasidone’s dopamine 
D
2
 receptor binding in healthy males using positron emission 
tomography demonstrated that doses less than 40 mg did not 
achieve adequate binding to reach antipsychotic effect;37 
however, increasing the dose from 60 mg to 80 mg did 
Table 1 Binding profile of the chemical lurasidone: endogenous neurotransmitter, characteristic activity type, and experimental Ki 
values associated with major receptors
Binding profile of lurasidonea
Receptor Neurotransmitter Activity Binding affinity (Ki)
b (nM)
D1 Dopamine Antagonist 262
D2 Dopamine Antagonist 1.68±0.09c
5-HT1A Serotonin Partial agonist 6.75±0.97
5-HT2A Serotonin Antagonist 2.03±0.46
5-HT2C Serotonin Antagonist 415
5-HT7 Serotonin Antagonist 0.495±0.090
α1A Norepinephrine Antagonist 47.9±7.8
α2A Norepinephrine Antagonist 40.7±7.7
α2C Norepinephrine Antagonist 10.8±0.64
H1 Histamine Antagonist .1,000
M1 Acetylcholine Antagonist .1,000
Notes: aexperimental values reported by ishibashi et al.22 bThe equilibrium dissociation constant, decreased value indicated increased affinity. cvalues are means ± standard 
error of the mean of three or more separate experiments.
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not effectively change receptor occupancy (77%–84% and 
73%–79%, respectively). This curve may explain, in part, 
why incidents of parkinsonism are infrequently seen, as there 
appears to be a dopamine receptor saturation point well below 
the threshold for extrapyramidal symptomology.
Lurasidone is primarily metabolized by CYP3A4, with 
the most common pathways being oxidative N-dealkylation, 
hydroxylation of the norbornane ring, and S-oxidation. The 
half-life, described in the product label as 18 hours, has been 
reported in some studies to be as long as 37 hours, given 
repeated oral doses at steady state.33 Several known pharma-
cologically active metabolites have been described such as 
ID-14283, ID-14326, and ID-11614 (25%, 3%, and ,1% of 
parent exposure, respectively).33 In vitro studies demonstrated 
that both ID-14283 and ID-14236 showed affinity for D
2
 and 
5-HT
2A
, as well as partial agonism at 5-HT
1A
 and antagonism 
at 5-HT
7
. ID-14283 may contribute to the parent compound’s 
efficacy, but has a shorter half-life (7 hours).21
Therapeutic efficacy
Though there now exists a growing body of literature detailing 
the pharmacokinetic properties of lurasidone, a complemen-
tary body of literature documenting its efficacy for the treat-
ment of bipolar I disorder is comparatively less due to the short 
time since initial approval.38 At the time of writing, only two 
controlled clinical trials have begun to investigate lurasidone 
as a treatment for bipolar I depression: as a monotherapy39 and 
as an adjunct treatment with lithium or valproate.40
The first of the two clinical trials was a randomized, 
double-blind, placebo-controlled, fixed-flexible dose study 
investigating the efficacy of lurasidone as a monotherapy 
treatment for bipolar I depression. Patients were randomly 
assigned to a 6-week treatment group of 20–60 mg/day of 
lurasidone (N=166; mean daily dose =31.8 mg), 80–120 mg/
day of lurasidone (N=169; mean daily dose =82.0 mg), or 
a placebo (N=170). The primary outcome measure was 
the change between baseline and week 6 scores on the 
Montgomery–Åsberg Depression Rating Scale (MADRS); 
a secondary outcome measure was the change in the depres-
sion severity score on the Clinical Global Impressions Scale 
for use in bipolar illness (CGI-BP).
The investigators reported significantly greater decreases 
in MADRS scores in both the 20–60 mg/day group (−15.4) 
and in the 80–120 mg/day group (−15.4) as compared to 
the placebo group (−10.7) (Figure 2A). Moreover, a sig-
nificantly greater reduction in core depressive symptoms 
(MADRS-6 subscale score) between baseline and week 6 
was also observed for the lurasidone 20–60 mg group (−10.4) 
and the lurasidone 80–120 mg group (−10.4) as compared 
to the placebo group (−6.9). A similar pattern was found in 
the CGI-BP scores for the 20–60 mg/day group (−1.8) and the 
80–120 mg/day group (−1.7) as compared to placebo (−1.1). 
Notably, these statistically significant decreases in MADRS 
and CGI-BP scores were observed in both dosage groups 
early in the course of treatment; differences between the 
groups in reported MADRS scores began at week 2, whereas 
Figure 2 Differences among behavioral outcomes by lurasidone treatment regimen between baseline and week 6 as measured by MADRS score and CGi-BP score.
Notes: (A) Mean change in MADRS from baseline to week 6 across different treatments in patients with bipolar i depression. (B) The mean change in depression severity 
score on the CGi scale from baseline to week 6 for the same treatment groups. Placebo, 20–60 mg/day and 80–120 mg/day values reported in Loebel’s monotherapy study;39 
adjunct experimental values from Loebel et al’s investigation of lurasidone as adjunctive treatment with lithium and valproate.40
Abbreviations: MADRS, Montgomery–Åsberg Depression Rating Scale; CGi-BP, Clinical Global impressions Scale for use in bipolar illness; d, day.
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differences in reported CGI-BP scores began at week 1 
for the 80–120 mg group and week 2 for the 20–60 mg 
group. Caution is warranted, however, in interpreting these 
results as the authors included neither standard deviations 
nor confidence intervals in the differences in MADRS or 
CGI-BP scores. Nonetheless 53% and 51% of subjects met 
response criteria (defined as $50% reduction from baseline 
in MADRS total) after 6 weeks of treatment with lurasi-
done 20–60 mg and lurasidone 80–120 mg, respectively, 
as compared to only 30% in the placebo group. Finally, the 
lurasidone 20–60 mg and lurasidone 80–120 mg groups both 
showed proportionately higher remission rates (42%; 40%) 
than did the placebo group (25%).
The second of the two clinical trials was also double 
blinded, but investigated lurasidone as an adjunct to lithium 
or valproate in the treatment of bipolar I depression. Inclu-
sion criteria required that patients should not have exhibited 
a response to a 28-day minimum trial of either lithium or 
valproate, prescribed at therapeutic levels, as determined 
by a health care professional. Qualifying patients were then 
randomly assigned to receive 6 weeks of lurasidone (N=183) 
or placebo (N=165) in addition to continuing their previously 
prescribed medication. Patients receiving lurasidone were 
initially administered a dosage of 60 mg; with each week 
after the first, health care professionals were allowed to adjust 
lurasidone doses by increments of 20 mg within a range of 
20–120 mg/day (the mean daily dose was 66.3 mg). As in 
the monotherapy study, the primary and secondary outcomes 
of interest were changes in the MADRS and CGI-BP scores, 
respectively, between baseline and week 6 of the trial.
Similar to the results of the monotherapy trial, signifi-
cantly greater decreases in MADRS and CGI-BP scores were 
observed for the adjunct lurasidone group (−17.1; −1.96) 
than for the placebo group (−13.5; −1.51) (Figure 2B). 
These differences were first observed beginning at week 3 
for the MADRS as well as at week 2 for the CGI-BP, and 
remained reliably different for the remainder of the trial. As 
mentioned earlier, caution is again warranted in interpreting 
these results as the authors included neither standard devia-
tions nor confidence intervals in the differences in MADRS 
or CGI-BP scores. Finally, greater proportions of patients met 
response criteria ($50% reduction from baseline in MADRS 
total) and remission (57%; 50%) than were observed in the 
placebo group (42%; 35%).
Although promising, these preliminary results regarding 
the therapeutic efficacy of lurasidone for the treatment of 
bipolar I depression should be considered with respect to 
the efficacy of preexisting treatments, specifically quetiapine 
and olanzapine–fluoxetine combination. Recently, Citrome 
et al41 compared the benefits of these three treatments using 
the number needed to treat (NNT) measure.42 As an indicator 
of effect size, NNT measures how many patients would need 
to be treated with one medication, on average, to observe 
one additional beneficial outcome of interest. Low NNTs 
are indicative of large effect sizes, with an example NNT 
of 2 indicating that on average, one of every two patients 
treated with a medication would receive the desired clinical 
benefit.
Citrome et al calculated the NNT for clinical response 
and remission for lurasidone based on the above two clini-
cal trials, as well as the NNT for quetiapine (immediate and 
extended release) and olanzapine–fluoxetine combination 
based on published 8-week trials and product labeling (see 
article for details).43 Of the three reviewed quetiapine stud-
ies, two studies set dosing levels at 300 mg/day and 600 mg/
day;43,44 the other prescribed quetiapine studies set dosing 
levels at 400 mg/day and 800 mg/day.45 In the two reviewed 
olanzapine–fluoxetine combination studies, the dosing levels 
were set at 6/25 mg/day, 6/50 mg/day, or 12/50 mg/day.46,47 
Clinical response was defined as a $50% reduction from 
baseline on the MADRS, whereas remission was defined 
as a final MADRS score of #12. For clinical response, 
NNT values of 5 (95% CI 3–8) and 5 (95% CI 4–11) were 
found for patients prescribed monotherapy lurasidone at low 
(20–60 mg/day) or high (80–120 mg/day) doses; an NNT 
value of 7 (95%, 4–24) was found for adjunct lurasidone 
(20–120 mg/day). In comparison, NNT values of 6 and 5 
were found for quetiapine and olanzapine–fluoxetine combi-
nation in clinical response, respectively. For clinical remis-
sion, an NNT value of 6 (95%, 4–14) was found for patients 
with a low dose (20–60 mg/day) of monotherapy lurasidone; 
an NNT value of 7 (95%, 4–21) was found for patients with 
a high dose (80–120 mg/day) of monotherapy lurasidone; 
and an NNT value of 7 (95%, 4–23) was found for patients 
with 20–120 mg/day adjunct dose of lurasidone. In com-
parison, NNT values of 6 and 4 were found for quetiapine 
and olanzapine–fluoxetine combination in clinical response, 
respectively.41,42 It is worth noting that 95% confidence inter-
vals were similarly not reported for the NNT values of the 
comparative treatments. Perhaps related to this, Citrome et 
al offer a conservative conclusion regarding the therapeutic 
efficacy of lurasidone relative to its predecessors, stating only 
that it yielded comparable benefits for treatment.
In summary, preliminary findings from two recent double-
blinded clinical trials suggest that lurasidone is efficacious in 
treating bipolar I depression, with clinical effects manifest-
ing as early as the first 2–3 weeks of treatment (as measured 
by MADRS and CGI-BP). Its therapeutic benefit, however, 
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appears to be comparable to other atypical antipsychotics, 
on average. This is in line with a recent meta-analysis of 
212 clinical trials of antipsychotic drugs in schizophrenia, 
spanning more than 43,000 patients, that found lurasidone to 
be similar (if not weaker) than quetiapine and olanzapine in 
alleviating symptoms.48 Of course, it is still early in the inves-
tigation of lurasidone, with both clinical trials detailed above 
extended to 24-week trials and data from weeks 6 to 24 still 
unpublished. Future research will no doubt shed further light 
as to the true utility of lurasidone for bipolar I depression.
The tolerability and safety 
of lurasidone
If lurasidone is neither superior nor inferior to other atypicals, 
might it have some advantage on the basis of side effects? 
Evidence on the tolerability and safety of lurasidone comes 
from two clinical trials in patients with bipolar depression and 
many clinical trials in schizophrenia patients. Head-to-head 
randomized clinical trials need to be conducted in order to 
conclusively evidence the relative superior or inferior effi-
cacy of lurasidone compared to other atypical antipsychotics. 
Although this article aims to review lurasidone in the context 
of bipolar depression, because there are only two published 
short-term studies of the drug in that patient population, it is 
important to also consider its safety and tolerability within 
schizophrenia patients.
Lurasidone was granted FDA approval for the treatment 
of schizophrenia in October 2010 and then in June 2013 
for bipolar depression.49 In reviewing relevant literature 
from 2009 to present, lurasidone has some evidence for 
a safety advantage over other recently approved second-
generation atypical antipsychotics, including paliperidone, 
iloperidone, and asenapine.41,50,51 De Hert et al showed that 
treatment with lurasidone in BD and schizophrenia is less 
likely to result in hypercholesterolemia, hyperglycemia, 
hyperlipidemia, and other metabolic side effects such 
as weight gain.41,50,51 Short-term studies of lurasidone in 
schizophrenia patients suggest that it is tolerable, safe, and 
has a low discontinuation rate.21 In schizophrenia trials, the 
most common adverse events included nausea, somnolence, 
akathisia, sedation, and parkinsonism.52 In an open-label 
6-month study in which 198 schizophrenic patients who 
were stable but symptomatic were switched to lurasidone, 
a total of 66.2% of patients had at least one adverse event, 
most of which were only mild or moderate.53 The study 
concluded that the drug was generally well tolerated and 
the investigators did not identify any new safety concerns. 
A handful of 1-year studies suggest that the long-term use of 
lurasidone is well tolerated in patients with schizophrenia, 
having similar discontinuation rates to patients receiv-
ing treatment with quetiapine XR (7% vs 5%).54,55 In this 
population, lurasidone appears to cause weight gain, but 
only modestly.21 Short-term clinical trials reported a mean 
increase in body weight of 26 kg in subjects treated with 
placebo and an increase in body weight of 75 kg in sub-
jects treated with lurasidone. Only 5.6% of subjects in the 
lurasidone group showed a weight gain of 7% or more, as 
compared with 4% of subjects in the placebo group.56 Caccia 
et al found that the weight gain was not dose related.21 In 
Citrome’s 6-month open-label study, 17 subjects reported 
weight loss (.7% of their body weight) from the study 
baseline, whereas only 14 patients reported weight gain of 
the same proportion.53 Although there is not much evidence 
regarding weight gain in long-term use of lurasidone in 
schizophrenia patients, lurasidone showed a more favor-
able effect on body weight compared with quetiapine and 
risperidone in two long-term trials.50,51
Evidence does not suggest that lurasidone induces 
clinically significant changes in glucose levels or other meta-
bolic parameters.57,58 In a pooled data analysis from short-
term studies on schizophrenia, Cucchiaro et al showed that 
the mean increases in fasting glucose levels were 1.4 mg/dL 
in subjects receiving lurasidone and 0.6 mg/dL in subjects 
receiving placebo, which is not a statistically significant 
difference.59 A long-term (12-month) study comparing 
lurasidone with quetiapine XR showed that there was no 
negative influence on glucose levels when taking lurasidone 
for an extended period.54
In short-term studies of lurasidone, there were no adverse 
events related to hyperlipidemia and there were no increases 
in low-density lipoprotein cholesterol, level of total choles-
terol, or triglycerides.59 In fact, one double-blind comparison 
study found that a decrease in triglycerides (−2.6 mg/dL) 
was associated with lurasidone, compared to an increase 
(+22.4 mg/dL) associated with ziprasidone.60 In a long-
term comparison study of risperidone and lurasidone, the 
median changes in low-density lipoprotein cholesterol levels 
and triglycerides in the lurasidone group were −2.0 mg/dL 
and −3.5 mg/dL, respectively.55
Lurasidone is absorbed quickly, reaching peak serum con-
centration in 1–3 hours.38 Maximum concentration increases 
three-fold when administered with food, indicating that the 
site of absorption is likely the stomach.61 In a study aiming 
to elucidate the target amount of food needed to maximize 
serum concentration, the mean C
max
 was 52.9 ng/mL in 
the fasted state, 161 ng/mL for the 350 kcal/high-fat meal, 
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135 ng/mL for the 500 kcal/high-fat meal, and 131 ng/mL for 
the 800–1,000 kcal/high-fat meal.62 Therefore, lurasidone is 
advised to be taken with about 350 kcal, although fat content 
per se does not appear to have an influence. Once absorbed, 
99.8% of it is bound to albumin and α-1-glycoprotein.33
Significant increases in prolactin levels were associated 
with lurasidone in several short-term studies in schizophrenia.21 
Pooled data from five short-term studies indicated that mean 
changes in prolactin levels were −0.6 ng/mL in the placebo 
group and +1.1 ng/mL in the lurasidone group.59 However, 
the prolactin changes due to lurasidone may be lower than 
those due to other similar drugs. One study found that mean 
changes in prolactin levels were greater in patients receiv-
ing haloperidol (+8.5 ng/mL) and olanzapine (+3.7 ng/mL) 
than lurasidone (+1.1 ng/mL).63 A long-term study that 
compared risperidone with lurasidone showed median 
changes in prolactin levels in the 0 ng/mL lurasidone group 
in male subjects and +0.95 ng/mL lurasidone group among 
female subjects. These levels were lower than those of 
the risperidone group, which were +7.50 ng/mL in males 
and +26.40 ng/mL in females.55
To date, there have been two peer-reviewed articles that 
investigated lurasidone in the treatment of bipolar I depression. 
Both of these were 6-week, randomized, double-blind, and 
placebo-controlled trials conducted by Loebel et al as reviewed 
earlier. In the monotherapy study, dropout rates due to adverse 
events were similar across all three groups, ranging from 5.9% 
to 6.6%. There were no statistically significant differences 
in the effect of treatment on metabolic parameters reported, 
including weight, lipid, prolactin or cholesterol levels, waist cir-
cumference, glycemic control, or electrocardiogram readings.39 
The percent of patients with a 7% or greater increase in weight 
from baseline was 0.7% in both the 80–120 mg and placebo 
groups and 4.2% in the 20–60 mg group. In general, the 
high-dose group experienced more adverse effects. Nausea 
was the most common (N=29, 17.4%), followed by akathisia 
(N=18, 10.8%), headache (N=15, 9.0%), extrapyramidal 
events (N=15, 9.0%), and sedation (N=12, 7.2%).39 Rates of 
serious adverse events were low across groups, and there were 
no deaths, suicidal behaviors, or suicides during the course of 
the study.39 In the second clinical trial, discontinuation rates 
were lower in the lurasidone + lithium/valproate group (6%) 
compared to the placebo + lithium/valproate group (7.9%).40 
The lurasidone + lithium/valproate group experienced more 
adverse effects than did the placebo + lithium/valproate group. 
In the group receiving lurasidone, the most common adverse 
event was nausea (N=32, 17.5%), followed by extrapyramidal 
events (N=28, 15.3%), somnolence (N=16, 8.7%), tremor 
(N=15, 8.2%), and akathisia (N=14, 7.7%).40 The percentage 
of subjects receiving lurasidone + lithium/valproate who expe-
rienced at least one adverse event was 63.9%, while the per-
centage of placebo + lithium/valproate subjects experiencing 
at least one adverse event was 57.7%. In this study, treatment 
with lurasidone was not associated with significant increases 
in weight, lipids, glucose, or prolactin levels.40
Dose adjustments are recommended for patients with 
either liver or kidney problems. Most of the deactivation 
of the drug is hepatic, and it should be taken with caution 
when in conjunction with strong CYP3A4 inhibitors (such 
as ketoconazole) or inducers (such as rifampin).38 Smoking 
is not expected to have an effect on the pharmacokinetics of 
lurasidone because it is not a substrate for CYP1A2.37 For 
patients with hepatic impairment, maximum doses should 
be 40 mg/day or 80 mg/day, depending on the Child–Pugh 
score. For patients with renal impairment, a maximum dose 
of 80 mg/day should be observed.38 Safety and tolerability 
have not been established in pediatric or geriatric populations. 
However, according to industry data, no dose adjustment was 
needed in 65–85-year old schizophrenia patients.64
The adverse effects experienced by patients receiving 
lurasidone for bipolar depression in the two clinical trials 
were similar to those experienced by schizophrenia patients 
receiving lurasidone. These two bipolar depression studies 
suggest that lurasidone could be safely used both as a mono-
therapy and as an adjunctive therapy.27 However, there is 
no evidence for long-term safety of lurasidone in bipolar 
patients, and additional clinical trials need to be conducted to 
establish sustained safety and tolerability within the bipolar 
patient population. There is reason for optimism; ziprasidone, 
a chemically similar agent, was suggested to have reduced 
metabolic side effects in early data, and these impressions 
have since been verified in much larger scale studies. 
A 2004 comparison study of risperidone and ziprasidone by 
Addington et al showed that ziprasidone had a significantly 
smaller effect on weight gain. In total, 16.0% (N=20) of 
risperidone patients experienced significant weight gain 
($7%), while only 8.2% of ziprasidone patients did.65 A 2014 
meta-analysis by Oh et al of 73 randomized clinical trials 
corroborated these early results, showing that treatment with 
ziprasidone, compared to six other antipsychotics, resulted 
in a substantially smaller chance of significant weight gain 
(odds ratios ranging from only 0.02 to 0.44).66
Conclusion
Lurasidone is a member of the second-generation atypi-
cal antipsychotics. Its recent approval by the FDA for 
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the treatment of bipolar depression has led to limited but 
potentially promising potential therapeutic efficacy for this 
disabling, prevalent, treatment-resistant disease. Lurasidone 
interacts as an antagonist with high affinity to D
2
 and 5-HT
2A
 
receptors, as do other members of its pharmaceutical class. 
Lurasidone, however, somewhat uniquely binds with high 
affinity to the 5-HT
7
 receptor, as well as acts as a partial 
agonist at the 5-HT
1A
 receptor. These neurobiological prop-
erties may lend procognitive, antidepressant, or anxiolytic 
effects to lurasidone. In addition, lurasidone interacts neg-
ligibly with receptors implicated in sedation, weight gain, 
and cardiovascular symptoms associated with other atypical 
antipsychotics.
Limited data are available concerning lurasidone’s clinical 
efficacy. Two 6-week double-blinded and randomized trials 
published promising decreases in MADRS and GCI-BP scores 
after treatment with lurasidone as a monotherapy as well as 
an adjunctive therapy with lithium or valproate. Moreover, 
these studies reported relatively limited extrapyramidal and 
metabolic side effects as a result of treatment with lurasidone, 
with the most common side effect being nausea. The caveat 
is that both studies were funded and overseen by lurasidone’s 
manufacturer and have not yet been independently replicated. 
The average weight change throughout the course of both 
studies was statistically insignificant. These advantages over 
other drugs within the same class, if further validated, could 
someday make lurasidone a preferable agent for patients with 
bipolar depression.
The safety of lurasidone for the treatment of bipolar 
depression is not strongly established, as there are few 
clinical data available. Safety data drawn from schizophre-
nia research indicate that, in comparison with other atypical 
antipsychotics, treatment with lurasidone is less likely to 
result in metabolic side effects such as weight gain or dis-
turbances of serum glucose or lipid levels. Lurasidone is best 
absorbed with approximately 350 kcal of food and is hepati-
cally metabolized by CYP3A4; thus, it should not be taken 
in conjunction with strong CYP3A4 inhibitors or inducers. 
Overall, the rates of adverse effects have been low; however, 
the data with bipolar depression patients remain limited.
In conclusion, lurasidone holds clinical potential as a 
novel, efficacious pharmacological treatment for bipolar 
depression. However, current data on its use in the bipolar I 
population are limited; more extensive research, both longer 
in duration as well as independently conducted, is needed.
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